BioSpace News Archive

Syngenta engaged university agricultural experts from across the U.S. to suggest solutions for the toughest weed management challenges farmers are facing

T-System, a CorroHealth company, is launching the App Showcase highlighting complementary solutions to their Emergency Department Information System (EDIS) platform.

Adaptive Phage Therapeutics Receives Orphan Drug Designation for PhageBank ™ in Prosthetic Joint Infections

Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced three poster presentations and one oral presentation at ASN’s Kidney Week 2020 Reimagined.

Vycellix, Inc., an immuno-centric discovery life science company with a focus on natural killer cell-based (NK cell) therapeutics, today announced that its Chairman & CEO, Evren Alici, M.D., Ph.D., will present at the upcoming Allogeneic Cell Therapies Summit.

NANTES, France, Oct. 22, 2020 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced a publication in the prestigious Journal of Clinical Investigation (JCI) of translational and preclinical study data in rodent in vivo and human ex vivo models characterizing the efficacy and mechanism of action of BI 765063, formerly OSE-172, the first selective antibody antagonist of SIRPα-mediated “Don’t Eat Me” signals. Importantly, for the first time ever the

Micro-Tech Endoscopy USA reveals their latest product launch in the GI market, EndoINK Endoscopic Marker. EndoINK is a single-use fluid designed to endoscopically mark lesions in the gastrointestinal tract

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Anthony Welters has been appointed to the company’s Board of Directors.

In lieu of an in-person update to the media, Dr. Theresa Tam, Canada’s Chief Public Health Officer, issued the following statement

MATWIN, a French open-innovation platform dedicated to promoting innovation in oncology, today announces the latest six projects to receive its backing. In virtual discussions, held on October 13 and 14, two panels selected the projects they believe offer the most promising opportunities for patients in the fight against cancer.